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Balanced production of type I interferons and proinflammatory cytokines, such as tumor necrosis factor (TNF), is proposed to have a key role in the pathogenesis of autoimmune diseases 1 . Furthermore, interferon production can suppress tumors, whereas TNF and other inflammatory cytokines can promote tumor growth 2, 3 . Yet the mechanisms that balance the production of type I interferon and pro inflammatory cytokines are poorly understood. The main receptors able to induce both cytokine classes are Tolllike receptors (TLRs), which respond to ligands of microbial, fungal, viral and mammalian origin [4] [5] [6] . Despite the deployment of common signaling pathways, such as mitogenactivated protein kinase (MAPK) cascades and transcrip tion factor NFκB signaling dependent on the kinase IKK, different TLRs elicit distinct biological responses, with some being more potent inducers of proinflammatory cytokines and others mainly inducing interferons and interferonrelated genes. The biochemical basis for the response specificity is poorly understood, although it has been attributed to differences in the deployment of adaptor proteins 7 and selective activation of interferonregulatory factors (IRFs), such as IRF3, by TLRs that trigger the interferon response 8 .
TLRs recruit four Toll-interleukin 1 (IL1) receptor (TIR) domaincontaining adaptors, including MyD88 (A003535), TRIF (A004068), TRAM and TIRAP, to their cytoplasmic TIR domains [9] [10] [11] [12] [13] [14] [15] . These adaptors control distinct responses classified as either MyD88 dependent or TRIF dependent 4, 16 . Whereas the MyD88dependent response mediates induction of proinflammatory cytokines, the TRIFdependent response is critical for the induction of interferons and interferon related genes 10, 11 . How the two responses are activated differently is unknown, but published studies have highlighted a critical role for the signaling protein TRAF3 (A002309) in the induction of interferon related genes and inhibition of inflammatory cytokines 17, 18 . However, TRAF3, which is necessary for IRF3 activation, interacts with both MyD88 and TRIF. Although TRAF3 positively regulates IRF3 and the type I interferon response 18 , it negatively regulates MAPK signaling by CD40 ligand and BAFF, members of the TNF family 19 . In contrast, the related protein TRAF6 positively controls MAPK signaling by TNF receptors and TLRs 20 . What makes TRAF3 function negatively in one response and positively in another is unknown. It is also unclear why MyD88, which interacts with TRAF3, does not lead to IRF3 activation after TLR4 engagement.
Using TLR4 as a prototypical TLR that elicits both MyD88 and TRIFdependent responses, we now show that differences in the ubiquitination of TRAF3 are the key to the selective production of type I interferons versus proinflammatory cytokines. TRIFmediated signaling triggered TRAF3 selfubiquitination through noncanonical polyubiquitination linked to the lysine at position 63 of the ubiquitin molecule (K63linked), which was essential for activation of IRF3 and the interferon response. In contrast, MyD88dependent signaling through TRAF6 and the ubiquitin ligases cIAP1 and cIAP2 (called 'cIAP1/2' here) resulted in degradative ubiquitination of TRAF3, which was required for MAPK activation and induction of pro inflammatory cytokines and chemokines. Elimination of cIAP1 and cIAP2 resulted in highly specific inhibition of proinflammatory genes without any effect on the antiinflammatory and tumorsuppressive interferon response.
RESULTS

MAPK signaling dependent on cIAP1/2 and MyD88
The ubiquitin ligases cIAP1 and cIAP2 are redundant E3 ubiqutin ligases that direct degradative (K48linked) ubiquitination of TRAF3 and are critical for twostage MAPK signaling induced by the costimulatory molecule CD40, in which assembly of the recep torassociated signaling complex is followed by translocation of the multiprotein complex to the cytosol, the site at which MAPK cascades are activated 19 . Using a smallmolecule mimetic of Smac (the antagonist of inhibitor of apoptosis protein), which triggers rapid cIAP1/2 degradation 21,22 , we found that cIAP1 and cIAP2 were also involved in TLR signaling. In bone marrow-derived macrophages (BMDMs) and the mouse macrophage line RAW264.7, pretreatment with the Smac mimetic (SM) inhibited activation of the MAPK kinase kinase TAK1, but not of IKK, by ligation of TLR4 and TLR2 ( Fig. 1a and Supplementary Fig. 1 ). SM had no effect on TAK1 MAPK activation by TLR3, which signals exclusively through TRIF. Congruently, TRIFdefective Trif Lps2/Lps2 BMDMs showed relatively intact lipopolysaccharide (LPS)induced TAK1MAPK activation through TLR4 that remained sensitive to treatment with SM, but residual TAK1MAPK activation in My88 −/− BMDMs was barely affected by SM (Fig. 1b) . Neither cIAP1 nor cIAP2 was involved in TRIFmediated signaling necessary for interferon expression, as pretreatment with SM did not prevent dimerization or nuclear translocation of IRF3 (Fig. 1c) . The effects of SM were specific, as RAW264.7 cells in which cIAP1/2 expression was silenced by short hairpin RNA (shRNA) specific for cIAP1/2, cIAP1/2deficient multiple myeloma cells or RAW264.7 cells incubated with a pro teasome inhibitor also showed defective LPSinduced activation of TAK1MAPK ( Supplementary Fig. 2a-c) . Furthermore, silencing of TRAF3 rendered RAW264.7 macrophages resistant to treatment with SM ( Supplementary Fig. 2d) . Hence, the E3 ligases cIAP1 and cIAP2, which trigger K48specific degradative ubiquitination of TRAF3 19, 23 , are important for MyD88dependent activation of MAPK but are dispensable for TRIFdependent induction of interferons.
TRAF3 and cytosolic translocation of MyD88 signaling complexes
To study the formation of TLR4associated signaling complexes, we separated BMDMs into membrane fractions (which contain plasma and endosomal membranes) and cytosolic fractions after LPS stimu lation and analyzed these by immunochemistry. LPS induced rapid but transient recruitment of MyD88, TRAF6, TRAF3, IKKγ (also known as NEMO), cIAP1/2, the ubiquitinconjugating enzyme Ubc13 and TAK1 to TLR4 and more persistent TRIF recruitment, which lasted at least 30 min (Fig. 2a) . TLR4 was not detected in the cytosolic fraction, but immunoprecipitation with antibody to TAK1 (antiTAK1) demonstrated the LPSinduced formation of a large cytosolic complex that persisted for at least 30 min after receptor stimulation and contained MyD88, TRAF6, IKKγ, cIAP1/2, Ubc13, the MAPK kinase MKK4 (which was not part of the receptor associated complex) and TAK1, but not TRAF3 or TRIF (Fig. 2a) . Pretreatment with SM stabilized the receptorassociated complex and prevented cytosolic translocation of the TAK1associated complex (Fig. 2a) . These results suggest that after assembly on the cytoplasmic face of TLR4, the MyD88nucleated signaling complex, containing TRAF6, IKKγ, cIAP1/2, Ubc13 and TAK1, translocates to the cytosol, leaving behind TLR4 and TRAF3, and incorporates MKK4. Translocation of the complex required cIAP1/2 and was therefore inhibited by pretreatment with SM, which also blocked the recruitment of MKK4 and phosphorylation of TAK1MAPK, which occurred in the cytosol and not at the receptor (Fig. 2a) .
Cytosolic translocation of the CD40assembled signaling complex requires the E3 ubiquitin ligase activity of cIAP1/2 and correlates with TRAF3 degradation 19 . We examined the fate of TRAF3, which was present in the TLR4anchored complex but was not part of the cytosolic TAK1associated complex. Total TRAF3 protein abundance rapidly, but incompletely, decreased within 10 min of LPS stimulation, whereas the abundance of total TRAF6 remained constant (Fig. 2b) . TRAF3 degradation was inhibited by pretreatment with SM. Similarly, TLR4associated TRAF3 rapidly decreased at 10 min after stimulation, and this degradation was inhibited by SM (Fig. 2b) . TLR4associated TRAF6, however, was unchanged between 5 and 10 min after LPS addition, but after 10 min it was undetectable except in cells pre treated with SM (Fig. 2b) . Notably, small amounts of TRAF3 remained associated with TLR4 even at 30 min after stimulation (Fig. 2b) . This residual TRAF3 was probably engaged in MyD88independent sign aling. Silencing of TRAF6 in RAW264.7 macrophages prevented the recruitment of TAK1 to TLR4 but had no effect on the recruitment of MyD88, TRIF or cIAP2, whereas silencing of TRAF3 did not affect the recruitment of any of these proteins (Fig. 2c) . Notably, silenc ing of TRAF6 slowed down disassociation of the MyD88assembled complex from the receptor.
Unlike TRAF2, however, TRAF6 does not interact directly with cIAP1/2 (ref. 24 and data not shown). As recruitment of cIAP2 to TLR4 was dependent on MyD88 but not TRIF (Supplementary Fig. 3a) , we examined whether MyD88 and TRIF can interact with cIAP1/2. Consistent with the genetic analysis, precipitation experiments with fusion proteins of glutathione Stransferase and MyD88 or TRIF showed an interaction between cIAP2 and MyD88 but not between cIAP2 and TRIF (Supplementary Fig. 3b ). However, it remains to be determined whether this protein interaction is direct.
It has been proposed that the recruitment of MyD88 and TRIF to the TIR domain of TLR4 is sequential and mutually exclusive 25, 26 . Consistent with the MyD88 dependence of the recruitment of cIAP2 to TLR4, immunoprecipitation of the membrane fraction with anti cIAP2 resulted in the isolation of TLR4 and MyD88 but not of TRIF (Supplementary Fig. 4a) . Furthermore, inhibition of TLR4 endo cytosis with the dynamin inhibitor dynasore 27 had no effect on the recruitment of MyD88 or cIAP2 to the receptor, but blocked TRIF recruitment (Supplementary Fig. 4b) . We conclude that TRIF and MyD88 are recruited to separate pools of receptors. Because SM inhibited the dissociation of MyD88 from the receptor without affecting TRIF recruitment, whereas dynasore inhibited TRIF recruit ment without affecting MyD88 recruitment, it seems that each adap tor is recruited independently to TLR4.
TRAF6 is required for ubiquitination of cIAP2 and TRAF3
We examined the effect of silencing TRAF3 and TRAF6 on TLR4 induced signaling responses. LPSinduced TAK1MAPK activation were barely detected in TRAF6deficient cells, whereas depletion of TRAF3 accelerated their activation (Fig. 3a,b) . However TRAF3 was required for IRF3 activation, but TRAF6 was not ( Supplementary  Fig. 5 ). LPS triggered polyubiquitination of cIAP2 and TRAF3 (Fig. 3c,d) . Total, K48linked and K63linked ubiquitination of cIAP2 were TRAF6 dependent but TRAF3 independent (Fig. 3c) . Depletion of TRAF6 diminished the total and K48linked, but not the K63 linked, polyubiquitination of TRAF3 (Fig. 3d) . Congruently, ablation of TRAF6 inhibited LPSinduced degradation of TRAF3 (Fig. 3a) . Likewise, treatment with SM inhibited total, but not K63linked, ubiq uitination of TRAF3 (Fig. 4a) , which suggests that cIAP1 and cIAP2 are responsible for K48linked ubiquitination of TRAF3, as observed during CD40 signaling 19 . Akin to TRAF2 during CD40 signaling 23 , TRAF6 may mediate TLR4induced activation of cIAP1 and cIAP2 through their K63linked ubiquitination and is therefore needed for TRAF3 degradation. As TRAF6 is a K63specific E3 ligase, the K48 linked ubiquitination of cIAP2 that shows TRAF6 dependence is most probably due to selfubiquitination by cIAP2 or cIAP1.
TLR3 also triggered K63linked ubiquitination of TRAF3 (Supplementary Fig. 6a) . Notably, the ratio of K63linked to total ubiquitination of TRAF3 was higher for TLR3, which signals exclu sively through TRIF. Indeed, TLR4induced K63linked ubiquitination of TRAF3 was TRIF dependent and MyD88 independent (Supplementary Fig. 6b ). In contrast, SMsensitive ubiquitination of TRAF3 was MyD88 dependent, consistent with its reliance on cIAP1 and cIAP2, which are recruited to TLR4 through MyD88. 
A r t i c l e s TRAF3 K63-linked ubiquitination depends on endocytosis
After activation, TLR4 undergoes dynamindependent endocytosis, which is required for TRIFdependent interferon signaling but not for MyD88mediated signaling 25 . As TRAF3 is a positive effector of the TRIFdependent interferon response, we examined whether its noncanonical K63linked ubiquitination was linked to TLR4 endo cytosis. Inhibition of TLR4 endocytosis with dynasore modestly diminished total LPSinduced ubiquitination of TRAF3 but strongly inhibited K63linked ubiquitination of TRAF3 (Fig. 4a) . Pretreatment with SM diminished total ubiquitination of TRAF3 but had no effect on its K63linked ubiquitination, whereas treatment with both SM and dynasore abolished ubiquitination of TRAF3 altogether (Fig. 4a) . Treatment with dynasore alone did not block activation of MAPKs or IKK (Supplementary Fig. 7) .
We isolated the endosomal compartment (Supplementary Fig. 8 ) at various points after TLR4 activation and analyzed its composition. LPS induced the association of TLR4, TRIF, TRAF6, TRAF3, Ubc13, TBK1 and TAK1, but not of MyD88 or cIAP2, with endosomes ( Fig. 4b) . Endosomal TRAF3 was K63 polyubiquitinated and did not undergo LPSinduced degradation. Treatment with dynasore prevented LPSinduced endocytosis of TLR4 and its associated proteins, but treatment with SM did not.
TRIFdependent K63linked ubiquitination of TRAF3 is associated with IRF3 activation and is akin to K63linked ubiquitination of TRAF6, thought to be due to RING finger-mediated selfubiquitination 28 . To determine whether K63linked ubiquitination of TRAF3 is also RING dependent, we introduced C68A and H70A substitutions, analogous to TRAF6inactivating substitutions 28 , into the TRAF3 RING finger. We silenced TRAF3 in cells and reconstituted the cells with either wild type TRAF3 or the RINGfinger mutant of TRAF3. Both TRAF3 forms underwent LPSinduced polyubiquitination, but K63linked polyubiq uitination of the RINGfinger mutant of TRAF3 was much less that of wildtype TRAF3 (Fig. 5a) . Congruently, in cells in which TRAF3 was silenced, reconstitution with either wildtype or RINGfingermutant TRAF3 delayed activation of TAK1MAPK, but only wildtype TRAF3 supported activation of IRF3 (Fig. 5b) . Furthermore, both TRAF3 isoforms resulted in less IL6 induction, but only wildtype TRAF3 supported the induction of type I interferon (Fig. 5c) .
We systematically substituted lysine residues with arginine residues throughout TRAF3 to identify acceptors for K48linked polyubiquitin chains. We combined single mutants with less ubiquitination to generate double mutants, among which TRAF3 with K107R and K156R substitu tions showed the greatest, but still incomplete, decrease in LPSinduced K48linked ubiquitination with little if any effect on K63linked ubiq uitination (Fig. 5d) . When expressed in macrophages in which TRAF3 was silenced, TRAF3 with K107R and K156R substitutions supported LPSinduced activation of IRF3 and induction of interferon mRNA, but it led to less activation of TAK1 and lower induction of IL6 mRNA than did wildtype TRAF3 (Fig. 5d-f) .
SM differentially affects TLR-mediated gene induction
To determine the role of the two different modes of ubiquitination of TRAF3 in TLR signaling, we downregulated cIAP1 and cIAP2, which are responsible for degradative ubiquitination of TRAF3 (refs. 23,29,30) by treating BMDMs with SM. This treatment inhibited the induction of genes encoding inflammatory cytokines and chemokines, including Tnf, Il6, Il12b, Il12a, Cxcl2 and Cxcl1, by LPS (TLR4 ligand) and Pam 3 CSK 4 (TLR2 ligand) but had no effect on their induction by poly(I:C) (TLR3 ligand; Fig. 6a and Supplementary Fig. 9a) . SM, however, had no effect on induction of the genes encoding interferonα and interferonβ or interferonrelated genes, including Il10, Cxcl10, Ccl5 and Ccl2, in response to any TLR agonist ( Fig. 6a and Supplementary Fig. 9a ). We noted similar effects on cytokine gene induction in cIAP1/2deficient RAW264.7 cells (Supplementary Fig. 9b ) and multiple myeloma cells (Supplementary Fig. 9c) . The cIAP1/2dependent induction of inflammatory cytokines by TLR4 was unique to the MyD88dependent response, as pretreatment with SM inhibited LPSinduced inflammatory cytokines and chemokines in Trif Lps2/Lps2 BMDMs, which were impaired in the induction of interferonrelated genes ( Fig. 6b and Supplementary  Fig. 9b ). In contrast, induction of interferonrelated genes and residual inflammatory cytokine gene expression in LPSstimulated Myd88 −/− BMDMs were not affected by pretreatment with SM. Hence, the two responses, one entailing induction of inflammatory cytokines and the other encompassing type I interferon and interferonrelated genes, are separately regulated and show differences in their sensitivity to SM.
DISCUSSION
TLRs detect microbes, viruses and endogenous ligands to mediate the induction of genes encoding inflammatory cytokines, chemokines, interferons and interferonrelated molecules 16 . In general, TLRs that recognize bacteria induce proinflammatory cytokines, chemokines and antimicrobial peptides, whereas those that detect viruses trigger the interferon response 31 . How these two responses, which depend on engagement of MyD88 and TRIF, are balanced to control auto immunity 1 and protumorigenic versus antitumorigenic inflammation 2 has remained unknown until now 32 . TRAF3 is uniquely required for the TRIFdependent interferon response 17, 18 , but it is also a negative regulator of MAPK activation 19 . We therefore explored the basis for the different activities of TRAF3 and examined whether TRAF3 is involved in determining the balance between inflammatory cytokines and type I interferons. We found that although TRAF3 was incorporated into both MyD88 and TRIFassembled multiprotein complexes, its signaling function was regulated in different ways by alternative ubiquitination modes. In the MyD88assembled signaling complex, TRAF3 underwent degradative K48linked ubiquitination depend ent on TRAF6 and on cIAP1 and cIAP2, the latter being direct K48 specific TRAF3 ubiquitin ligases 19, 23 . Notably, cIAP1 and cIAP2 were present only in the MyD88assembled signaling complex but not in the TRIFassembled signaling complex. Degradative ubiquitination of TRAF3 in the MyD88 complex precluded IRF3 activation and instead promoted cytosolic translocation of the entire signaling complex. This allowed MAPK activation and induction of inflammatory genes. In contrast, the association of TRAF3 with the cIAP1/2 devoid, endosomal TRIF signaling complex resulted in its K63linked selfpolyubiquitination, a modification that was required for IRF3 activation and induction of the interferon response. It should be noted that MyD88 and TRIF are not part of the same signaling complex and differences in their signaling potentials correlate with their ability to selectively engage cIAP1/2 and thereby dictate the nature of TRAF3 ubiquitination. Despite the absence of cIAP1/2, the TRIFassembled signaling complex can also activate TAK1 to some extent and this may have accounted for the weak induction of inflammatory cytokines that was SM resistant, seen in MyD88deficient cells.
The TRAF3 relatives TRAF2 and TRAF6 are E3 ubiquitin ligases that selectively catalyze K63linked polyubiquitination of themselves 33 and other proteins, such as cIAP2 (ref. 23) . Their activity depends on Ubc13, a K63specific ubiquitinconjugating enzyme 33 that is essential for TNF receptor and TLRinduced activation of MAPK 34 . We have now demon strated that as with its relatives, the TRAF3 RING finger was required for its K63linked ubiquitination in the TRIF signaling complex, but unlike TRAF2 or TRAF6, K63linked ubiquitination of TRAF3 was not totally dependent on Ubc13 (unpublished results), which thus explains the activation of the interferon response in Ubc13deficient cells 34 . Notably, during MyD88 or CD40 signaling 19 , TRAF3 did not undergo K63linked selfubiquitination and instead acted as an inhibitor of MAPK acti vation and inflammatory cytokine induction. This inhibitory activity did not require the RING finger of TRAF3 and was eliminated after its proteasomal degradation, which was promoted by its 'decoration' with canonical K48linked polyubiquitin chains. The extent of K63linked ubiquitination of TRAF3 correlated with interferon induction, being the highest for TLR3stimulated macrophages. In the case of TLR4, K63linked ubiquitination of TRAF3, just like IRF3 activation, depended on receptor endocytosis and TRIF rather than MyD88. Our results have demonstrated that MyD88dependent MAPK sign aling proceeds through a two stage mechanism, similar to that described before for CD40 and other TNF receptors 19 . This mechanism involves receptorinduced assembly of a multiprotein complex containing MyD88, TRAF6, Ubc13, IKKγ, cIAP1/2, TAK1 and TRAF3. Complex assembly resulted in TRAF6 activation, which led to K63linked ubiq uitination of cIAP1 and cIAP2 and enhancement of their activity as TRAF3 K48specific E3 ligases 19, 23 . Degradation of TRAF3 allowed translocation of the MyD88associated signaling complex to the cytosol, where TAK1 and its subordinate MAPKs are activated. Interference with this process by SMinduced elimination of cIAP1/2 selectively inhibited the induction of inflammatory cytokines and chemokines without any deleterious effect on the interferon response, which includes induction of the antiinflammatory cytokine IL10. Notably, activation of IKK by TLR4, which also depends on TAK1 (ref. 35 and data not shown), was not affected by SMinduced inhibition of TAK1 phosphorylation. This suggests that unlike MAPK signaling, IKK activation depends on TAK1 but not on its protein kinase activity, an important concept that merits further investigation. Although it did not prevent NFκB activa tion, interference with twostage TLR signaling through SMinduced elimination of cIAP1/2 was sufficient for selective inhibition of the production of inflammatory cytokines and chemokines but had no deleterious effect on the interferon response. We therefore propose that SM and similar cIAP1/2 antagonists may serve as superior anti inflammatory drugs that will not compromise antiviral immunity. This may be of importance in inflammatory diseases that respond to type I interferons 1 , as well as cancer whose growth is stimulated by proinflam matory cytokines, such as TNF, but is inhibited by type I interferons 2 . Furthermore, selective inhibition of TNF and other proinflammatory cytokines without a concomitant decrease in interferon production may be useful in the treatment of autoimmune disease caused by increased TNF and decreased type I interferons 1 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/. Accession codes. UCSDNature Signaling Gateway (http://www. signalinggateway.org): A003535, A004068 and A002309.
